

Aptar Pharma Acquires Worldwide License for Orbital™ High Payload Dry Powder Inhaler

License will help Aptar Pharma meet growing global demand for safe and convenient administration of high dose treatments to the lungs.

Crystal Lake, Illinois, August 4, 2022 - Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has acquired the worldwide rights to clinical stage drug developer Pharmaxis' proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.

The Orbital technology helps meet an increasing global need to deliver high doses of drugs, such as antibiotics, to the lungs and allows powder payloads of up to 400mg to be inhaled by patients in divided doses without the need to reload. This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (mannitol).



Dry Powder Inhaler (DPI) Orbital™

Howard Burnett, Vice President Global Pulmonary Category, Aptar Pharma commented, "With this acquisition, Aptar Pharma is pleased to be building on our current expertise for the treatment of chronic conditions. As a recognized global leader in respiratory drug delivery devices and associated services, we now have a wider offering to meet our customer needs."

Gary Phillips, CEO Pharmaxis added, "I am delighted that Aptar Pharma, who are one of the world's foremost drug delivery device companies, have seen the potential in the Orbital technology. We look forward to them building on the technical evaluations carried out during the option period and delivering new product solutions that can benefit drug developers and patients. Today's announcement is a further example of our strategy to generate non-dilutive cash from the mannitol respiratory business."



This acquisition strengthens Aptar Pharma's leadership in respiratory by offering a broader range of devices and services, from formulation to patient. Coupled with their formulation expertise at Nanopharm, Human Factors and patient onboarding at Noble, analytical services at Next Breath – all Aptar Pharma companies - as well as their Digital Health offering, Aptar Pharma is able to optimize device design, customize drug development and differentiate with improved compliance to provide their customers with a value-added finished product.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

About Pharmaxis

Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue. Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au.

#

Media Contact

Ciara Jackson

Aptar Pharma

+49 151 1951 6502

ciara.jackson@aptar.com